The estimated Net Worth of Capital Management, L.P.Kol... is at least $107 Million dollars as of 29 September 2020. Capital Kol owns over 950,000 units of Pandion Therapeutics stock worth over $102,701,413 and over the last 4 years Capital sold PAND stock worth over $4,093,182.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Capital Kol PAND stock SEC Form 4 insiders trading
Capital has made over 7 trades of the Pandion Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital bought 950,000 units of PAND stock worth $17,100,000 on 29 September 2020.
The largest trade Capital's ever made was buying 3,333,333 units of Pandion Therapeutics stock on 14 July 2020 worth over $59,999,994. On average, Capital trades about 936,004 units every 10 days since 2020. As of 29 September 2020 Capital still owns at least 1,710,265 units of Pandion Therapeutics stock.
You can see the complete history of Capital Kol stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Pandion Therapeutics
Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol..., and Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.
What does Pandion Therapeutics's logo look like?
Complete history of Capital Kol stock trades at TG Therapeutics Inc, Nkarta, iTeos Therapeutics, Inozyme Pharma, Inhibrx, Dyne Therapeutics, Pmv Pharmaceuticals Inc, and Pandion Therapeutics
Pandion Therapeutics executives and stock owners
Pandion Therapeutics executives and other stock owners filed with the SEC include:
-
Capital Management, L.P.Kol...,
-
Nancy Stagliano,
Director -
Vikas Goyal,
See Remarks -
Joanne L. Viney,
See Remarks -
Partners Gp Viii, L.L.C.Pol...,
-
Rizzuto Carlo,
Director -
Jill Carroll,
Director -
Katina Dorton,
Director -
Donald Frail,
Director -
Christopher Fuglesang,
Director -
Gregg Beloff,
See Remarks -
Alan L Crane,
Director -
Mitchell Mutz,
Director -
Eric D Larson,
Vice President, Finance -
Daniel J. Becker,
Director -
Rahul Kakkar,
Chief Executive Officer -
Plc Gsk,
Director -
John Sundy,
Chief Medical Officer -
Edward D. Freedman,
Chief Operating Officer